We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


UK Biobank Pharma Proteomics Project Publishes Early Results From its Pioneering Proteomics Research

UK Biobank Pharma Proteomics Project Publishes Early Results From its Pioneering Proteomics Research content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Olink Holding AB (publ) (Nasdaq: OLK) has announced that a publication describing the early findings of proteomics research conducted by the UK Biobank Pharma Proteomics Project (UKB-PPP) was published online to the bioRxiv preprint server, and is available here.

The study, titled “Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants,” utilized Olink® Explore 1536 and genome sequencing on 54,306 UK Biobank participants to gather and analyze data from protein quantitative trait loci (pQTL) mapping of 1,463 proteins identifying 10,248 primary genetic associations, of which 85% have not been previously reported.

The results from the UKB-PPP publication provide an updated genetic atlas of the plasma proteome and provide the scientific community with an open-access, population-scale proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries. Measuring thousands of proteins at population scale has promise to improve our understanding of underlying mechanisms of disease, and therefore accelerate the development of novel biomarkers and therapeutics. Furthermore, the study highlights the strengths of Olink’s Explore assay for pQTL detection and downstream biological discovery, with a high proportion, 82% of the proteins tested, having cis associations, evidence of Olink’s highly specific assays that measure their intended proteins.

“The landmark research conducted by members of the UKB-PPP is a meaningful early step in harnessing the power of next-generation proteomics in combination with genetic information to improve human health," said Jon Heimer, CEO of Olink. "We are extraordinarily grateful that Olink’s Explore platform can be part of this tremendous journey, and eagerly await the full data set to be released to the scientific community by the end of this year."

The UK Biobank Pharma Proteomics Project is a collaboration between UK Biobank and thirteen biopharmaceutical companies, and is currently performing one of the world’s largest scientific studies of blood protein biomarkers. The UK Biobank is a large-scale, biomedical database and research resource containing in-depth genetic and health information from half a million UK participants. The database is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. UKB-PPP aims to enable better understanding of disease biology and support innovative drug development for more effective therapies.